The effects of calcium antagonists on extracellular potassium accumulation during global ischaemia in isolated perfused rat hearts.

Abstract:

:The effects of equipotent concentrations of diltiazem, verapamil, and nifedipine upon the accumulation of extracellular potassium [K+]out and the left ventricular pressure (LVP) were studied during global ischemia in isolated perfused rat hearts. Measurement of [K+]out and LVP were performed in two series of experiments. Diltiazem (2 x 10(-6), 3 x 10(-6), and 10(-5) M), verapamil (3 x 10(-8), 10(-7), and 3 x 10(-7) M), and nifedipine (3 x 10(-8), 10(-7), and 1.5 x 10(-7) M) were able to slow, in a concentration-dependent manner, the initial rate of rise of [K+]out without affecting the final plateau value of [K+]out reached at t = 5 to t = 10 minutes. Notably, at the lowest concentrations, which slightly influenced LVP diltiazem, verapamil, and to a lesser degree nifedipine, were still able to slow the rise in [K+]out. In addition, after preperfusion with low-calcium media [( Ca2+] from 1.8 to 1.3 or 0.9 mM), inducing similar negative inotropic effects as those of the calcium antagonists, the rise in [K+]out was not significantly influenced. Our data indicate that the ability to slow the rise in [K+]out is a specific characteristic of calcium antagonists that is independent of their negative inotropic effects.

journal_name

Cardiovasc Drugs Ther

authors

Heijnis JB,Coronel R,van Zwieten PA

doi

10.1007/BF00143532

subject

Has Abstract

pub_date

1991-12-01 00:00:00

pages

1035-41

issue

6

eissn

0920-3206

issn

1573-7241

journal_volume

5

pub_type

杂志文章
  • Calcium channel antagonists: Part VI: Clinical pharmacokinetics of first and second-generation agents.

    abstract::A survey of the pharmacokinetic properties of the three prototypical calcium antagonist agents shows that they have in common a very high rate of hepatic first-pass metabolism with, in the case of verapamil and diltiazem, the formation of an active metabolite that affects the dose during chronic therapy. Therefore, th...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1007/BF01865507

    authors: Opie LH

    更新日期:1989-08-01 00:00:00

  • Vasoconstriction induced by ouabain in the canine coronary artery: contribution of adrenergic and nonadrenergic responses.

    abstract::Ouabain, when applied to rings of the left circumflex coronary artery of the dog (which contains both alpha 1-adrenoceptors leading to contraction and beta 1-adrenoceptors leading to relaxation) caused an initial contraction which peaked within 15 minutes and a later secondary increase in tension which peaked within 6...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/BF00051242

    authors: Cooke JP,Shepherd JT,Vanhoutte PM

    更新日期:1988-07-01 00:00:00

  • Amiodarone plus Ranolazine for Conversion of Post-Cardiac Surgery Atrial Fibrillation: Enhanced Effectiveness in Reduced Versus Preserved Ejection Fraction Patients.

    abstract:PURPOSE:Ranolazine (RAN) added to amiodarone (AMIO) has been shown to accelerate termination of postoperative atrial fibrillation (POAF) following coronary artery bypass surgery in patients without heart failure (HF). This study aimed to investigate if treatment efficacy with AMIO or AMIO + RAN differs between patients...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s10557-018-6832-8

    authors: Simopoulos V,Hevas A,Hatziefthimiou A,Dipla K,Skoularigis I,Tsilimingas N,Aidonidis I

    更新日期:2018-12-01 00:00:00

  • Combination Therapy of Pulmonary Arterial Hypertension with Vardenafil and Macitentan Assessed in a Human Ex Vivo Model.

    abstract:PURPOSE:Treatment of pulmonary arterial hypertension (PAH) by vasodilator drug monotherapy is often limited in its effectiveness. Combination therapy may help to improve treatment and to reduce drug toxicity. This study assessed the combination of the endothelin receptor antagonist macitentan and the phosphodiesterase-...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/s10557-019-06868-y

    authors: Hoenicka M,Golovchenko S,Englert L,Spaeth M,Shoshiashvili L,Großer C,Hofmann HS,Ried M

    更新日期:2019-06-01 00:00:00

  • Differential ability of human endothelial cells to internalize and express exogenous DNA.

    abstract::Vascular endothelium gene expression regulates blood-vessel wall interactions, vascular permeability, smooth muscle cell growth and tone. The possibility to introduce exogenous DNA or RNA sequences in endothelial cells represents a novel therapeutic approach of vascular disease. The aim of the work was to investigate ...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1023/a:1011154616992

    authors: Colombo MG,Citti L,Basta G,De Caterina R,Biagini A,Rainaldi G

    更新日期:2001-01-01 00:00:00

  • Identifying the Dominant Contribution of Human Cytochrome P450 2J2 to the Metabolism of Rivaroxaban, an Oral Anticoagulant.

    abstract:PURPOSE:Rivaroxaban, an oral anticoagulant, undergoes the metabolism mediated by human cytochrome P450 (CYP). The present study is to quantitatively analyze and compare the contributions of multiple CYPs in the metabolism of rivaroxaban to provide new information for medication safety. METHODS:The metabolic stability ...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/s10557-020-07129-z

    authors: Zhao T,Chen Y,Wang D,Wang L,Dong P,Zhao S,Wang C,Meng Q,Sun H,Liu K,Wu J

    更新日期:2021-01-07 00:00:00

  • Effect of encainide, ODE, MODE, and flecainide on ADP/5-HT induced platelet aggregation and in the anesthetized dog coronary artery stenosis-occlusion model of intravascular thrombosis.

    abstract::Encainide is a class 1C antiarrhythmic agent that is indicated for the treatment of life-threatening arrhythmias, such as sustained ventricular tachycardia. Furthermore, encainide possesses a moderate degree of antiserotonin activity, which was quantitated in this present study by determining displacement of [3H]spipe...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/BF03029752

    authors: Fleming JS,Buchanan JO,Yocca FD,Iben LG,Antonaccio MJ

    更新日期:1991-08-01 00:00:00

  • Renal effects of calcium entry blockers.

    abstract::Calcium entry blockers exert several characteristic effects on renal function that contribute to their blood-pressure lowering capacity. They are able to dilate renal vasculature and, in certain circumstances, can increase the glomerular filtration rate, both effects being dependent on the preexisting vascular tone. C...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1007/BF02018304

    authors: Ruilope LM,Alcazar JM

    更新日期:1990-08-01 00:00:00

  • Quinapril hydrochloride effects on renal function in patients with renal dysfunction and hypertension: a drug-withdrawal study.

    abstract::Patients with mild to moderate hypertension (diastolic blood pressure > or = 95 and < or = 115 mmHg) and renal dysfunction entered one of two studies to assess the safety of efficacious daily doses of quinapril on renal function and blood pressure. Twenty-four patients with moderate renal impairment (MRI) (creatinine ...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1007/BF00877336

    authors: Miller MA,Texter M,Gmerek A,Robbins J,Shurzinske L,Canter D

    更新日期:1994-04-01 00:00:00

  • Myocardial ischemia and reperfusion: the role of oxygen radicals in tissue injury.

    abstract::Thrombolytic therapy has gained widespread acceptance as a means of treating coronary artery thrombosis in patients with acute myocardial infarction. Although experimental data have demonstrated that timely reperfusion limits the extent of infarction caused by regional ischemia, there is growing evidence that reperfus...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1007/BF00133206

    authors: Werns SW,Lucchesi BR

    更新日期:1989-01-01 00:00:00

  • Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference.

    abstract:PURPOSE:The need for novel approaches to cardiovascular drug development served as the impetus to convene an open meeting of experts from the pharmaceutical industry and academia to assess the challenges and develop solutions for drug discovery in cardiovascular disease. METHODS:The Novel Cardiovascular Therapeutics S...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1007/s10557-017-6739-9

    authors: Povsic TJ,Scott R,Mahaffey KW,Blaustein R,Edelberg JM,Lefkowitz MP,Solomon SD,Fox JC,Healy KE,Khakoo AY,Losordo DW,Malik FI,Monia BP,Montgomery RL,Riesmeyer J,Schwartz GG,Zelenkofske SL,Wu JC,Wasserman SM,Roe MT

    更新日期:2017-08-01 00:00:00

  • Comparison of the efficacy of atenolol and its combination with slow-release nifedipine in chronic stable angina.

    abstract::There is still uncertainty of whether combined therapy with a beta-blocker and calcium-channel antagonist provides additive or synergistic clinical benefits in most patients with stable angina pectoris. The comparative antianginal effect of atenolol 50 mg and atenolol 50 mg and slow release nifedipine (20 mg) twice a ...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/BF00877726

    authors: Meyer TE,Adnams C,Commerford P

    更新日期:1993-12-01 00:00:00

  • Influence of the new class I antiarrhythmic agent diprafenone on the end-systolic pressure-volume relationship (conductance technique).

    abstract::To evaluate cordiodepressive risks of antiarrhythmic treatment with diprafenone, we monitored, in addition to conventional hemodynamic parameters, end-systolic pressure-volume relations to assess potential negative inotropic effects. Thirteen patients underwent hemodynamic analysis with and without the influence of di...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/BF01883858

    authors: Thormann J,Kramer W,Kremer P,Schlepper M

    更新日期:1989-04-01 00:00:00

  • Cost-effectiveness of different strategies for stroke prevention in patients with atrial fibrillation in a health resource-limited setting.

    abstract:PURPOSE:To compare the lifetime cost and effectiveness of five alternative chronic atrial fibrillation (AF) management strategies: rivaroxaban, warfarin, aspirin plus clopidogrel, aspirin and no prevention. METHODS:An individual-level state-transition model was developed to track the lifetime disease course associated...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/s10557-013-6490-9

    authors: Wu B,Kun L,Liu X,He B

    更新日期:2014-02-01 00:00:00

  • The initial hemodynamic response to newer antihypertensive agents at rest and during exercise: review of visacor, doxazosin, nisoldipine, tiapamil, perindoprilat, pinacidil, dilevalol, and carvedilol.

    abstract::Antihypertensive drugs may lower blood pressure through very different mechanisms, initially as well as during chronic use. This article is a review of the immediate hemodynamic changes induced by a beta blocker (visacor), an alpha-receptor blocker (doxazosin), two calcium antagonists (tiapamil and nisoldipine), an an...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/BF01856510

    authors: Omvik P,Lund-Johansen P

    更新日期:1990-08-01 00:00:00

  • The efficacy of nifedipine and acebutolol in coronary artery disease assessed by radionuclide ventriculography.

    abstract::The efficacy of a fixed combination of 10 mg nifedipine and 100 mg acebutolol was tested in 21 patients with angiographically proven coronary artery disease (CAD). Ejection fraction (EF), emptying and filling rate (VS and VD), and end-systolic volume (ESV) were assessed by means of radionuclide ventriculography at res...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/BF00148473

    authors: Bauer R,Busch U,Lutilsky L,van de Flierdt E,Langhammer HR,Pabst HW

    更新日期:1989-06-01 00:00:00

  • Mechanistic studies of AVE3085 against homocysteine in endothelial protection.

    abstract:PURPOSE:Homocysteine (Hcy) is an independent risk factor for cardiovascular diseases that impairs endothelial function. We investigated whether the impaired endothelial function can be restored by the eNOS transcription enhancer AVE3085 in porcine coronary arteries. The effects of AVE3085 against Hcy on eNOS-NO functio...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/s10557-013-6478-5

    authors: Yang Q,Xue HM,Underwood MJ,Yu CM

    更新日期:2013-12-01 00:00:00

  • Enoximone: true inotropic effects? Do they cause ischemia? Analysis of end-systolic pressure-volume relations using the conductance (volume) catheter technique.

    abstract::True positive inotropy of enoximone is hard to prove clinically. It could increase the risk of myocardial ischemia when used in coronary artery disease (CAD). The analysis of the end-systolic pressure-volume relationship (ESPVR) as a load-independent parameter of the contractile left ventricular function (LVF) allows ...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/BF02018269

    authors: Thormann J,Hueting J,Kremer P,Wissemann J,Mitrovic V,Dieterich HA,Schlepper M

    更新日期:1990-10-01 00:00:00

  • Effects of Dipeptidyl Peptidase-4 Inhibitor Linagliptin on Left Ventricular Dysfunction in Patients with Type 2 Diabetes and Concentric Left Ventricular Geometry (the DYDA 2™ Trial). Rationale, Design, and Baseline Characteristics of the Study Population.

    abstract:PURPOSE:A multicentre, randomized, double-blind, placebo-controlled, parallel-group study aimed to define the potential positive effect of dipeptidyl peptidase-4 inhibition on left ventricular systolic function (LVSF) beyond glycemic control in type 2 diabetes mellitus (T2DM) (DYDA 2™ trial). METHODS:Individuals with ...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/s10557-019-06898-6

    authors: Giorda CB,Cioffi G,Lucci D,Nada E,Ognibeni F,Mancusi C,Latini R,Maggioni AP,DYDA 2 Investigators.

    更新日期:2019-10-01 00:00:00

  • When is discontinuation of antihypertensive therapy indicated?

    abstract::Major advances have been established in the handling of hypertensive vascular disease in recent years. However, drug compliance, drug costs, and the side effects of antihypertensive agents have prompted the question of whether intermittent therapy or even possible removal of medication represents an alternative to lif...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1007/BF02026496

    authors: Schmieder RE,Rockstroh JK

    更新日期:1990-12-01 00:00:00

  • Pharmacodynamic interactions of levosimendan and felodipine in patients with coronary heart disease.

    abstract:OBJECTIVE:The aim was to study the pharmacodynamic interactions and safety of the co-administration of the calcium sensitizer levosimendan and the calcium antagonist felodipine in patients with coronary heart disease (CHD) and with normal ejection fraction (EF). METHODS:The study was a randomized, double blind, placeb...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1023/b:card.0000015860.08185.6d

    authors: Põder P,Eha J,Antila S,Heinpalu M,Planken U,Loogna I,Mesikepp A,Akkila J,Lehtonen L

    更新日期:2003-09-01 00:00:00

  • Heart Failure in Women--Insights from the Framingham Heart Study.

    abstract::In the latter half of the 20th century, among participants of the Framingham Heart Study, incidence of heart failure (HF) has declined by about a third in women but not in men and survival after the onset of HF has improved in both sexes; however, HF remains highly lethal with over 50% dying within 5 years after onset...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1007/s10557-015-6599-0

    authors: Kenchaiah S,Vasan RS

    更新日期:2015-08-01 00:00:00

  • Similar antiischemic effects of intracoronary atenolol and nifedipine during brief coronary occlusions in humans.

    abstract::To compare the antiischemic effects of intracoronary administration of a beta blocker, atenolol, and of a calcium antagonist, nifedipine, on the clinical and electrocardiographic signs of myocardial ischemia induced by balloon occlusion of the coronary artery, we studied 32 consecutive patients undergoing routine PTCA...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/BF00051147

    authors: Ghio S,De Servi S,Angoli L,Bramucci E,Eleuteri E,Raffaghello S,Specchia G

    更新日期:1992-06-01 00:00:00

  • Effect of the cardioselective, sarcolemmal K(ATP) channel blocker HMR 1098 on atrial electrical remodeling during pacing-induced atrial fibrillation in dogs.

    abstract:PURPOSE:The progressive shortening of the atrial effective refractory period (ERP) during atrial fibrillation (AF) might be due to the activation of the KATP channels by rapid atrial rates. We tested the hypothesis that the cardioselective, sarcolemmal KATP channel blocker HMR 1098 would prevent atrial ERP shortening d...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1023/B:CARD.0000025752.63337.b2

    authors: Vereckei A,Gögelein H,Wirth KJ,Zipes DP

    更新日期:2004-01-01 00:00:00

  • Recombinant human interleukin-1 receptor antagonist provides cardioprotection during myocardial ischemia reperfusion in the mouse.

    abstract:PURPOSE:Acute myocardial infarction (AMI) drives an intense inflammatory response that contributes to infarct healing and cardiac remodeling. Recently, different studies have identified a role of interleukin-1 (IL-1) in the development of adverse cardiac remodeling. However, in animal models of AMI IL-1 has been shown ...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/s10557-012-6389-x

    authors: Toldo S,Schatz AM,Mezzaroma E,Chawla R,Stallard TW,Stallard WC,Jahangiri A,Van Tassell BW,Abbate A

    更新日期:2012-06-01 00:00:00

  • Antiischemic effects of nicorandil during coronary angioplasty in humans.

    abstract::The present study was undertaken on 10 patients with angina undergoing percutaneous transluminal coronary angioplasty. The angioplasty procedure consisted of two successive 30-second balloon inflations at 5 minute intervals. After the first inflation, nicorandil (0.1 mg/kg) was given intravenously over a 2-minute peri...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 临床试验,杂志文章

    doi:10.1007/BF00878473

    authors: Saito S,Mizumura T,Takayama T,Honye J,Fukui T,Kamata T,Moriuchi M,Hibiya K,Tamura Y,Ozawa Y

    更新日期:1995-03-01 00:00:00

  • Antiplatelet and anticoagulant therapies in acute coronary syndromes.

    abstract::The combination of aspirin and clopidogrel is the mainstay antiplatelet therapy for acute coronary syndromes (ACS). However, the dosing of aspirin, the dosing of clopidogrel, the timing of clopidogrel initiation as well as the duration of clopidogrel therapy remain controversial matters. Clopidogrel resistance is an e...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1007/s10557-009-6212-5

    authors: Hanna EB,Glancy DL,Saucedo JF

    更新日期:2010-02-01 00:00:00

  • Cost-effectiveness analysis of rivaroxaban plus aspirin versus aspirin alone in secondary prevention among patients with chronic cardiovascular diseases.

    abstract:PURPOSE:This study aimed to investigate the cost-effectiveness of low-dose rivaroxaban plus aspirin versus aspirin alone for patients with stable cardiovascular diseases in the Taiwan setting. METHODS:We constructed a Markov model to project the lifetime direct medical costs and quality-adjusted life-years of both the...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章

    doi:10.1007/s10557-020-07059-w

    authors: Lee MC,Liao CT,Toh HS,Chou CC,Chang WT,Chen ZC,Wu WS,Yu T,Strong C

    更新日期:2020-09-10 00:00:00

  • Correction to: Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)?

    abstract::The original version of this article unfortunately contained a mistake. There was a typo in the second sentence of the paragraph under the section Was the Dose of Drugs Fair?; "320 mg twice a day" should read "160mg twice a day". The corrected paragraph is shown below. ...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,已发布勘误

    doi:10.1007/s10557-018-6834-6

    authors: Ahn R,Prasad V

    更新日期:2018-12-01 00:00:00

  • Future Directions to Establish Lipoprotein(a) as a Treatment for Atherosclerotic Cardiovascular Disease.

    abstract::In both epidemiologic and genetic studies, increased levels of Lp(a) have been associated with increased risk for cardiovascular diseases as well as aortic stenosis. However, until recently, it has been difficult to lower levels of Lp(a). Diet and lifestyle have little effect on plasma levels of Lp(a) which are mainly...

    journal_title:Cardiovascular drugs and therapy

    pub_type: 杂志文章,评审

    doi:10.1007/s10557-016-6654-5

    authors: Stein EA,Raal F

    更新日期:2016-02-01 00:00:00